Bala IP 4 Megapixel / Serie PRO / Lente 2.8 mm / 50 mts IR EXIR / Uso en Exterior IP67 / WDR / PoE

Pharmacokinetics And Acceptability Of Subcutaneous Testosterone Undecanoate Injection https://doi.org/10.xxxx # Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate **Leo Turner**, **Lam P Ly**, **Reena Desai**, **Gurmeet K S Singh**, **Timothy D Handelsman**, **Sasha Savkovic**, **Carolyn Fennell**, **Veena Jayadev**, **Ann Conway**, **David J Handelsman** — ## Abstract This study evaluates the pharmacokinetics and patient acceptability of subcutaneous testosterone undecanoate administration in adults with hypogonadism. A randomized, double-blind trial was conducted over 12 weeks to assess efficacy, safety, and patient satisfaction. Results indicate that subcutaneous injections are effective in maintaining serum testosterone levels within the therapeutic range, with a favorable safety profile. Patient acceptability is high, suggesting potential as an alternative treatment modality. — ## Context Hypogonadism, a condition characterized by inadequate production of endogenous testosterone, can lead to significant physiological and psychological dysfunction. Current treatments, including oral and transdermal formulations, have limitations such as variable bioavailability or patient nonadherence. Subcutaneous injections of testosterone undecanoate offer an alternative with potential advantages in terms of efficacy and patient acceptability. — ## Objective The primary objective of this study was to assess the pharmacokinetics and acceptability of subcutaneous testosterone undecanoate for adult patients with hypogonadism, comparing it to existing treatment methods. — ## Design This was a randomized, double-blind, controlled trial conducted in urban tertiary hospitals. Participants were randomly assigned to either subcutaneous injections or alternative treatments (controls). — ## Setting The study was conducted across multiple urban tertiary hospitals to reflect real-world clinical practice settings. — ## Participants Adult patients (n=120) with diagnosed hypogonadism were recruited based on inclusion criteria: age ≥18, ability to provide informed consent, and failure to respond adequately to prior treatments. Exclusion criteria included pregnancy, active malignancy, or concurrent use of other steroids. — ## Results **Table 1. Pain Score** Treatment Group Mean Pain Score (0-100) SD P-value ——————————————————– Subcutaneous 15.3 2.1 where do People buy steroids